Clinical Trial

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Study acronym: ConTTRibute
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Protocol Amendment History 3 changes
critical Primary endpoint(s) modified 2026-05-30
notable Primary completion pushed: 2030-09-01 -> 2033-12-31 2026-05-30
minor Completion pushed: 2030-09-01 -> 2033-12-31 2026-05-30
Trial Details
NCT Number NCT04561518
Lead Sponsor Alnylam Pharmaceuticals
Conditions Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Enrollment 1,500 participants
Start Date 2020-11-23
Primary Completion 2033-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29